Skip to main content

Potential Drug Interactions

  • Drug interactions with warfarin may occur via several mechanisms, including impairment of absorption, induction or inhibition of metabolism, competition for protein-binding sites, and platelet inhibition. Drugs that inhibit or induce P-450 2C9 (responsible for metabolism of S-warfarin) may have the greatest effect on INR.

  • INR should be monitored more frequently in pediatric patients who are already on warfarin therapy and are starting on antibiotics.

  • Warfarin dosing can be adjusted to permit use of some medications that have an effect on warfarin metabolism. Please consult Hematology for adjustment recommendations.

Table 6. Commonly used Drugs in Children that affect INR Values

Drug

INR Effect

Mechanism

Amiodarone

Increase

Decreases warfarin metabolism

Antifungal agents

Increase

Fluconazole, ketoconazole, and miconazole (vaginal) decrease warfarin metabolism

Barbiturates

Decrease

Increase warfarin metabolism

Carbamazepine

Decrease

Increase warfarin metabolism

Cephalosporins

Increase

Inhibits production of vitamin K dependent clotting factors

Ciprofloxacin

Increase

Displace warfarin from binding sites (possible mechanism; not fully known)

Clarithromycin

Increase

Decrease warfarin metabolism

Contraceptives (Oral)

Increase

Increase clotting factor synthesis; may inhibit oxidative metabolism

Corticosteroids

Increase

Produce hypercoagulability; may have ulcerogenic effects

Delaviridine

Increase

May inhibit warfarin metabolism

Erythromycin

Increase

Decrease warfarin metabolism

Ibuprofen

Increase

May inhibit warfarin metabolism in addition to platelet inhibition

Indomethacin

Increase

May inhibit warfarin metabolism in addition to platelet inhibition

Isoniazid

Increase

May inhibit warfarin metabolism

Losartan

Increase

May inhibit warfarin metabolism

Omeprazole

Increase

May inhibit of warfarin metabolism

Metronidazole

Increase

Inhibits metabolism of S-isomer

Nicardipine

Increase

May inhibit warfarin metabolism

Pantoprazole

Increase

May inhibit warfarin metabolism

Penicillins

Increase

May enhance warfarin metabolism; May reduce GI flora synthesis of vitamin K

Phenytoin / fosphenytoin

Decrease

Increase warfarin metabolism; induces warfarin metabolism; displaces warfarin from protein-binding sites; enhances metabolism of clotting factors

Rifampin

Decrease

Induces hepatic enzymes, increases warfarin metabolism

Sulfamethoxazole - Trimethoprim (Bactrim)

Increase

Sulfonamide component may stereo-selectively inhibit S-isomer metabolism

Vitamin K

(ADEK, Centrum, Viactiv)

Decrease

Effects of oral anticoagulants are directly antagonized by the excessive ingestion of foods or dietary supplements containing vitamin K

Zafirlukast

Increase

May inhibit warfarin metabolism



Other important interactions

Drug

Effect

Mechanism

Aspirin, NSAIDs

Increased risk of bleed

Inhibition of platelet aggregation

Anti-platelet agents (dipyridamole, clopidrogel, ticlopidine, cilostazol)

Increased risk of bleed

Inhibition of platelet aggregation

 

References

Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008). Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133(6 Suppl), 160s-198s. https://doi.org/10.1378/chest.08-0670



Bolton-Maggs, P., & Brook, L. (2002). The use of vitamin K for reversal of over-warfarinization in children. Br J Haematol, 118(3), 924. https://doi.org/10.1046/j.1365-2141.2002.03631_5.x

David, M., et al. (2004, May). Warfarin Therapy in Children. Thrombosis Interest Group of Canada. Retrieved Oct 21, 2008 from http://www.tigc.org/eguidelines/warfarinchildren04.htm.



Horton, J. D., & Bushwick, B. M. (1999). Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician, 59(3), 635-646.



Lexicomp Online, Pediatric and Neonatal Lexi-Drugs. Kcentra. Retrieved Oct 2008, from https:online.lexi.com. 

Lexicomp Online, Pediatric and Neonatal Lexi-Drugs. Warfarin. Retrieved Oct 2008, from https:online.lexi.com.

Monagle, P., Chan, A. K. C., Goldenberg, N. A., Ichord, R. N., Journeycake, J. M., Nowak-Göttl, U., & Vesely, S. K. (2012). Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl), e737S-e801S. https://doi.org/10.1378/chest.11-2308



Monagle, P., Cuello, C. A., Augustine, C., Bonduel, M., Brandão, L. R., Capman, T., Chan, A. K. C., Hanson, S., Male, C., Meerpohl, J., Newall, F., O'Brien, S. H., Raffini, L., van Ommen, H., Wiernikowski, J., Williams, S., Bhatt, M., Riva, J. J., Roldan, Y., . . . Vesely, S. K. (2018). American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv, 2(22), 3292-3316. https://doi.org/10.1182/bloodadvances.2018024786



Roach, E. S., Golomb, M. R., Adams, R., Biller, J., Daniels, S., Deveber, G., Ferriero, D., Jones, B. V., Kirkham, F. J., Scott, R. M., & Smith, E. R. (2008). Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke, 39(9), 2644-2691. https://doi.org/10.1161/strokeaha.108.189696

These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.